Friday, March 20, 2015 2:42:38 PM
Every company does its best to put a positive light on developments, and this is completely expected. That is a different matter from what has been alleged to have happened in some other companies that were accused of issuing deliberately misleading releases. The commercialization path for VNTH lies through the FDA, and trials are a key part of that journey. At the present stage, one might ask, in light of the below releases, about the outcomes of the claimed trials.
From the November 20, 2014 press release:
"Vantage expects to further update its shareholders this winter on preliminary clinical trial results derived from using the new sensor for human breath."
From the July 2014 SEC filing:
"It is anticipated that preliminary human trials for the Vantage Health Sensor will begin next month at Scripps Translational Science Institute, paid for by a BioPharma partner of the Company."
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM